187 related articles for article (PubMed ID: 19148468)
1. Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Nakamura K; Abarzua F; Kodama J; Hongo A; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2009 Feb; 34(2):345-53. PubMed ID: 19148468
[TBL] [Abstract][Full Text] [Related]
2. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
[TBL] [Abstract][Full Text] [Related]
3. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2009 Aug; 35(2):239-48. PubMed ID: 19578736
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
5. Secretory leukoprotease inhibitor inhibits cell growth through apoptotic pathway on ovarian cancer.
Nakamura K; Takamoto N; Hongo A; Kodama J; Abrzua F; Nasu Y; Kumon H; Hiramatsu Y
Oncol Rep; 2008 May; 19(5):1085-91. PubMed ID: 18425362
[TBL] [Abstract][Full Text] [Related]
6. Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines.
Nakamura K; Nasu Y; Hongo A; Matsuo T; Kodama J; Ebara S; Nagai A; Abrzua F; Kumon H; Hiramatsu Y
Int J Oncol; 2006 Feb; 28(2):393-8. PubMed ID: 16391794
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
Gynecol Oncol; 2004 Sep; 94(3):725-34. PubMed ID: 15350365
[TBL] [Abstract][Full Text] [Related]
8. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
9. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
[TBL] [Abstract][Full Text] [Related]
10. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
Kauppinen JM; Kosma VM; Soini Y; Sironen R; Nissinen M; Nykopp TK; Kärjä V; Eskelinen M; Kataja V; Mannermaa A
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2133-42. PubMed ID: 20716618
[TBL] [Abstract][Full Text] [Related]
11. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis.
Ponnusamy MP; Venkatraman G; Singh AP; Chauhan SC; Johansson SL; Jain M; Smith L; Davis JS; Remmenga SW; Batra SK
Cancer Lett; 2007 Jun; 251(2):247-57. PubMed ID: 17210225
[TBL] [Abstract][Full Text] [Related]
12. Expression of matriptase and clinical outcome of human endometrial cancer.
Nakamura K; Hongo A; Kodama J; Abarzua F; Nasu Y; Kumon H; Hiramatsu Y
Anticancer Res; 2009 May; 29(5):1685-90. PubMed ID: 19443387
[TBL] [Abstract][Full Text] [Related]
13. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Ann Oncol; 2009 Jan; 20(1):63-70. PubMed ID: 18689863
[TBL] [Abstract][Full Text] [Related]
15. Biological role and prognostic significance of NAC1 in ovarian cancer.
Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
[TBL] [Abstract][Full Text] [Related]
16. Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.
Hu C; Jiang N; Wang G; Zheng J; Yang W; Yang J
J BUON; 2014; 19(1):215-20. PubMed ID: 24659667
[TBL] [Abstract][Full Text] [Related]
17. Loss of membrane-bound serine protease inhibitor HAI-1 induces oral squamous cell carcinoma cells' invasiveness.
Baba T; Kawaguchi M; Fukushima T; Sato Y; Orikawa H; Yorita K; Tanaka H; Lin CY; Sakoda S; Kataoka H
J Pathol; 2012 Oct; 228(2):181-92. PubMed ID: 22262311
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2010 Sep; 37(3):605-14. PubMed ID: 20664929
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
20. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
Köbel M; Gradhand E; Zeng K; Schmitt WD; Kriese K; Lantzsch T; Wolters M; Dittmer J; Strauss HG; Thomssen C; Hauptmann S
Int J Gynecol Pathol; 2006 Apr; 25(2):121-30. PubMed ID: 16633060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
